The bank rated companies like Thermo Fisher Scientific and Agilent at Buy, Illumina and PerkinElmer at Hold, and Myriad Genetics and Luminex at Sell.
Bruker said it plans to use InVivo assets to explore antibody enrichment methods that could eliminate the need for culturing prior to MALDI-based microbial ID.
Bioyong will invest in test development as well as validation, regulatory approval, and commercialization in China and, possibly, other Asia-Pacific countries.
The investment bank provided the updates as part of its 2017 outlook on the US life science tools and diagnostics markets.
The company said Scils will bolster its MALDI imaging offerings while InVivo will help with development of new content for its MALDI Biotyper business.
The company recently acquired intellectual property and personnel to drive development of PCR tests for applications including syndromic microbiology testing.
In addition to Illumina and Thermo Fisher, the investment bank reinitiated coverage of Bruker, Invitae, Agilent, Waters, and T2 Biosystems.
The company posted revenues of $393.6 million, short of Wall Street estimates of $394.1 million. It beat analysts' EPS estimates with earnings of $.32 per share.
The report focused on identification of filamentous fungi and mycobacteria, and testing for resistance and susceptibility to antibiotics.
The analyses found solid evidence that MALDI-based clinical microbiology systems bettered patient care, but effects on hospital costs were less clear.
In Science this week: metagenomic-based technique for determining protein structure, and more.
An academic laments the rise of narcissism in the sciences, the Guardian reports.
Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.
The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.